Clinical Trials in Social Media: Content Analysis of YouTube Videos in Arabic Language (Preprint)

2020 ◽  
Author(s):  
Amal Tabba' ◽  
Linda Kateb ◽  
Maysa Al-Hussaini
Keyword(s):  
Social Media ◽  
Clinical Trials ◽  
Phase I ◽  
Arabic Language ◽  
Phase Iii ◽  
Sources Of Information ◽  
Animal Testing ◽  
Phase I Clinical Trials ◽  
The Public ◽  
Youtube Videos

BACKGROUND Clinical trials are fundamental to the advancement of cancer care; nonetheless, recruitment remains inadequate. A frequently reported barrier to participation is the lack of awareness and knowledge about clinical trials. Research showed that the internet is being used now as a primary source for information on clinical trials. OBJECTIVE We aim in this study to review available videos uploaded on the YouTube, one of the most-visited websites worldwide, about clinical trials in Arabic language and evaluate the comprehensiveness of its content. METHODS YouTube videos were searched using the keywords “clinical trials” and “clinical studies” in Arabic language. Only videos targeting the public were included in the study. Videos targeting medical students/ healthcare professionals, discussing country-specific laws, longer than 30 minutes, or found irrelevant upon viewing were excluded from the analysis. RESULTS Seven videos about clinical trials were included in the final analysis. Only 1 video was related specifically to cancer clinical trials (14.3%). The mean length of videos was 6:43 minutes (range: 1:37-16:53 minutes) with a total number of views of 11,207 (mean 1,601.0, SD ±2,054.6). More than half of the videos (n=4, 57.1%) were created by TV/ Internet Channels and were neutral in tone. Most common presentation style and country of origin were vlog and Saudi Arabia, receptivity (n=3, 42.9% for both). For video-related content, the most frequently mentioned variables were the purpose of clinical trials to test new drug/devices in humans (n=6, 85.7%), animal testing conducted before clinical trials, clinical trials are conducted on several phases, phase I clinical trials and the aim of phase I studies is to assess safety (n=5, 71.5%; for all items). These were followed by mention of phase II and phase III in general (n=4, 57.1%; for both items). CONCLUSIONS This study identified a clear scarcity of YouTube videos about clinical trials in the Arabic language, as well as, potential gaps in the comprehensiveness of the content presented. Viewers’ engagement presented in number of views, likes and dislikes seems to be very low. Stakeholders need to pay more attention to the use of social media in prompting clinical trials and providing comprehensive and reliable sources of information to the public. CLINICALTRIAL None

scholarly journals Self-Replicating RNA Viruses for RNA Therapeutics

Molecules ◽  
2018 ◽  
Vol 23 (12) ◽  
pp. 3310 ◽  
Author(s):  
Kenneth Lundstrom
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Tumor Cells ◽  
Neutralizing Antibodies ◽  
Ebola Virus ◽  
Vaccine Development ◽  
Rna Viruses ◽  
Antibody Responses ◽  
Phase Iii ◽  
Phase I Clinical Trials

Self-replicating single-stranded RNA viruses such as alphaviruses, flaviviruses, measles viruses, and rhabdoviruses provide efficient delivery and high-level expression of therapeutic genes due to their high capacity of RNA replication. This has contributed to novel approaches for therapeutic applications including vaccine development and gene therapy-based immunotherapy. Numerous studies in animal tumor models have demonstrated that self-replicating RNA viral vectors can generate antibody responses against infectious agents and tumor cells. Moreover, protection against challenges with pathogenic Ebola virus was obtained in primates immunized with alphaviruses and flaviviruses. Similarly, vaccinated animals have been demonstrated to withstand challenges with lethal doses of tumor cells. Furthermore, clinical trials have been conducted for several indications with self-amplifying RNA viruses. In this context, alphaviruses have been subjected to phase I clinical trials for a cytomegalovirus vaccine generating neutralizing antibodies in healthy volunteers, and for antigen delivery to dendritic cells providing clinically relevant antibody responses in cancer patients, respectively. Likewise, rhabdovirus particles have been subjected to phase I/II clinical trials showing good safety and immunogenicity against Ebola virus. Rhabdoviruses have generated promising results in phase III trials against Ebola virus. The purpose of this review is to summarize the achievements of using self-replicating RNA viruses for RNA therapy based on preclinical animal studies and clinical trials in humans.

The role of phase I clinical trials in advanced malignant melanoma: Retrospective analysis of CTEP-sponsored trials 1995-2011.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 2606-2606
Author(s):  
Jason John Luke ◽  
Larry Rubinstein ◽  
Gary L Smith ◽  
S. Percy Ivy ◽  
Pamela Jo Harris
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Phase 1 ◽  
Therapeutic Benefit ◽  
Phase Iii ◽  
Phase I Trials ◽  
Toxicity Data ◽  
Phase I Clinical Trials ◽  
Exact Test ◽  
Phase Iii Clinical Trials

2606 Background: Standard chemotherapy for melanoma is DTIC (RR ~10%). Many physicians do not refer to phase I due to perceived limited clinical benefit (CB=CR+PR+SD) and increased toxicity. To understand the actual experience of melanoma patients (pts) in phase I trials, we analyzed the outcomes of melanoma pts treated on CTEP phase 1 trials (1995-2011) and compared them to DTIC. Methods: We queried the CTMS of CTEP for phase I trials in which advanced melanoma pts were treated. Trials were separated into targeted (T), chemo (C) and immunotherapy (I). Pt characteristics, response and toxicity data were collected. Chemotherapy included chemo with targeted or immunotherapy. Toxicity was drug related if attributed possibly, probably or definitely to drug. Fisher’s Exact Test (2-sided p) was used to compare groups. DTIC data was pooled from 6 modern phase III clinical trials (1999-2011). Results: 937 pts (M595:F342) participated in 148 trials (T: 68, C: 53, I: 27). Characteristics included (median) Age: 51.5 yrs; ECOG status: 0; Prior therapies: 2 (majority receiving prior DTIC); LDH: 206 and albumin: 4.1. Response and toxicity data are shown in the Table. Targeted therapy was associated with lower RR (p=.01), immuno with lower CB rate (p<.001) and chemo with higher incidence of G4 toxicity (p<.001) relative to the other groups. Comparing phase 1 to DTIC, RR and CB were not clinically different (phase I: 6.3% and 26.8% vs. DTIC: 8.8% and 27.9%) but G3-4 toxicity was significantly higher (54% vs. 28%) in phase I (p<.0001). Conclusions: Melanoma pts in prior CTEP phase I trials, a majority DTIC pre-treated, had similar therapeutic benefit but more toxicity compared to DTIC naïve pts in modern clinical trials. [Table: see text]

scholarly journals Unconventional Anticancer Agents: A Systematic Review of Clinical Trials

2006 ◽  
Vol 24 (1) ◽  
pp. 136-140 ◽  
Author(s):  
Andrew J. Vickers ◽  
Joyce Kuo ◽  
Barrie R. Cassileth
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Patients ◽  
Phase Ii ◽  
Dose Finding ◽  
Phase Iii ◽  
High Dose ◽  
Free Text ◽  
Phase Ii Trials ◽  
Off Label

Purpose A substantial number of cancer patients turn to treatments other than those recommended by mainstream oncologists in an effort to sustain tumor remission or halt the spread of cancer. These unconventional approaches include botanicals, high-dose nutritional supplementation, off-label pharmaceuticals, and animal products. The objective of this study was to review systematically the methodologies applied in clinical trials of unconventional treatments specifically for cancer. Methods MEDLINE 1966 to 2005 was searched using approximately 200 different medical subject heading terms (eg, alternative medicine) and free text words (eg, laetrile). We sought prospective clinical trials of unconventional treatments in cancer patients, excluding studies with only symptom control or nonclinical (eg, immune) end points. Trial data were extracted by two reviewers using a standardized protocol. Results We identified 14,735 articles, of which 214, describing 198 different clinical trials, were included. Twenty trials were phase I, three were phase I and II, 70 were phase II, and 105 were phase III. Approximately half of the trials investigated fungal products, 20% investigated other botanicals, 10% investigated vitamins and supplements, and 10% investigated off-label pharmaceuticals. Only eight of the phase I trials were dose-finding trials, and a mere 20% of phase II trials reported a statistical design. Of the 27 different agents tested in phase III, only one agent had a prior dose-finding trial, and only for three agents was the definitive study initiated after the publication of phase II data. Conclusion Unconventional cancer treatments have not been subject to appropriate early-phase trial development. Future research on unconventional therapies should involve dose-finding and phase II studies to determine the suitability of definitive trials.

scholarly journals Random-effects meta-analysis for systematic reviews of phase I clinical trials: Rare events and missing data

2016 ◽  
Vol 8 (2) ◽  
pp. 124-135 ◽  
Author(s):  
Mi-Ok Kim ◽  
Xia Wang ◽  
Chunyan Liu ◽  
Kathleen Dorris ◽  
Maryam Fouladi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Missing Data ◽  
Phase I ◽  
Random Effects ◽  
Systematic Reviews ◽  
Rare Events ◽  
Meta Analysis ◽  
Phase I Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document